Description
Quantity: 2 x 10⁶ cells
Unit Size: Each
Manufactured by MTI-GlobalStem and equivalent to MTI-GlobalStem Cat. No. GSC-6204G, these MEF cells are isolated from DR4 x CF1 hybrid mice, mitotically arrested by irradiation, and tested to help ensure safety and performance. For other variants of drug-resistant MEFs, see CF6-Neo Mouse Embryonic Fibroblasts, Irradiated or CF6-Neo Mouse Embryonic Fibroblasts, MitC-Treated. You may also choose from our selection of non-drug-resistant MEFs to suit your application.• Help save precious time with pre-inactivated, ready-to-use MEFs• Culture ESCs and iPSCs with confidence using meticulously tested feeder cells• Perform drug selection with MEFs that are resistant to neomycin/geneticin, puromycin, hygromycin, and 6-thioguanineHelp save time with ready-to-use MEFsIrradiated DR4 MEFs help save time and trouble dealing with an animal facility, performing tedious, time-consuming dissections, as well as expanding and testing cells day after day, week after week. Focus on your research with these pre-inactivated, ready-to-use feeders.Culture with meticulously tested feeder cellsEach lot of DR4 MEFs is tested for bacteria, fungi, mycoplasma, and various mouse pathogens to minimize the risk of contamination. Each lot is also tested for post-thaw viability (typically greater than 95%) and ability to support mouse and human ESCs to help ensure robust and consistent performance. These MEFs have successfully been used with ESC/iPSC lines from other species, but should be tested for compatibility if used for such an application.Perform drug selection with multidrug-resistant cellsDR4 MEFs express transgenes that make them resistant to four different drugs: geneticin (G418), puromycin, hygromycin, and 6-thioguanine. Each lot is tested for tolerance to various concentrations of these drugs and the threshold range for survival is reported in the certificate of analysis to aid in designing experiments. Use these feeder cells to support undifferentiated ESC or iPSC culture while performing drug selection.
